Pen Needles Market Size, Share, Growth, Analysis, Report, 2034


Date:

(MENAFN- Straits Research) Pen Needles Market Size

The global pen needles market size was valued at USD 3.73 billion in 2025 and is projected to grow from USD 4.17 billion in 2026 to USD 10.10 billion by 2034, registering a CAGR of 11.7% during the forecast period from 2026 to 2034. North America dominated the pen needles market with a market share of 38.6% in 2025.

Pen needles are short, thin needles attached to insulin pens and some other medication pens. They allow medication to be injected beneath the skin, and are typically replaced after each use.

Pen Needles Market Key TakeawaysGlobal Market Size & Growth2025 Market Size USD 3.73 Billion2026 Market Size USD 4.17 Billion2034 Projected Market Size USD 10.10 BillionForecast Period 2026–2034Base Year 2025Market CAGR (2026–2034) 11.7%Regional Insights Largest Regional Market (2025) North America North America Market Share (2025) 38.6% Fastest-Growing Region Europe Europe CAGR (2026–2034) 9.28%Segment Insights By Product Type Fastest-Growing Segment Safety Pen Needles CAGR 9.31% (2026–2034) By Needle Length Leading Segment 4mm Market Share in 2025 31.5% By Therapy Type Fastest-Growing Segment GLP-1 CAGR 10.36% (2026–2034) By Usability Fastest-Growing Segment Disposable Pens CAGR 9.16% (2026–2034)

Download a Free Sample To learn more about this report.

01

Ultra-Thin-Wall Needle Technology Improves Insulin Flow

The pen needles market analysis shows that the need for smoother insulin delivery and reduced injection effort is encouraging the adoption of ultra-thin-wall needle technology. These needles use thinner internal walls to create a wider inner diameter while maintaining a compact external diameter, allowing insulin to flow more easily during injection. This development supports improved injection performance, reduced delivery time, and greater convenience for people managing diabetes.

02

Shorter Pen Needles Improve Subcutaneous Injection Precision

The need to deliver insulin into subcutaneous tissue while minimizing the risk of intramuscular injection is encouraging the adoption of shorter pen needles. Needle lengths such as 4 mm and 5 mm support consistent subcutaneous delivery across different patient groups when used with appropriate injection techniques. This transition improves injection convenience, supports patient confidence, and reduces concerns associated with deeper needle penetration.

Pen Needles Market Dynamics 01

Prevalence of Diabetes Drive Market

The expanding patient population with type 1 and type 2 diabetes supports demand for pen needles used for regular insulin administration and blood glucose management. Patients who require insulin therapy depend on reliable injection devices to maintain prescribed treatment schedules and manage blood glucose levels. The need for consistent insulin administration across long-term diabetes care supports the adoption of pen needles.

02

Adoption of Insulin Pen Devices Incereas Market Demand

The preference for insulin pens over conventional vial-and-syringe systems encourages pen needle consumption due to their portability, ease of handling, and suitability for routine insulin delivery. Insulin pens offer a convenient administration method for patients who require frequent injections and allow compatibility with disposable or reusable pen needle formats. The increasing use of insulin pen-based delivery systems supports demand for compatible pen needles across home and clinical care settings.

03

Impact Analysis of Key Drivers in Pen Needles Market

DriversMarket Impact
Prevalence of Diabetes The expanding patient population with type 1 and type 2 diabetes supports demand for pen needles used for regular insulin administration and blood glucose management.
Adoption of Insulin Pen Devices The preference for insulin pens over conventional vial-and-syringe systems encourages pen needle consumption due to their portability, ease of handling, and suitability for routine insulin delivery.
Demand for Home-Based Diabetes Management The shift toward self-administered diabetes care supports the use of pen needles among patients who require frequent insulin injections outside healthcare facilities.
Diabetes Care Infrastructure Wider availability of diabetes clinics, pharmacies, specialty healthcare services, and patient education programs improves access to insulin delivery devices and supports pen needle adoption.
Awareness of Diabetes Management and Treatment Adherence Greater awareness of regular insulin administration and effective diabetes management encourages patients to use convenient injection devices, including insulin pens and compatible pen needles.
01

Risk of Needlestick Injuries and Improper Usage Creates Safety Concerns

Pen needles require proper handling, usage, and disposal to ensure safe insulin administration. Improper injection techniques, repeated needle usage, and accidental needle exposure can increase the risk of needlestick injuries, contamination, and injection-related complications. These safety concerns can reduce patient confidence, create challenges in maintaining consistent usage practices, and increase the need for proper patient education and safe disposal systems.

02

High Cost of Advanced Pen Needles Limits Patient Affordability

Advanced pen needles incorporate ultra-thin designs, specialized coatings, and safety features that require additional manufacturing precision and quality-control measures. These technologies can increase production expenses and result in higher retail prices compared with conventional pen needles. The additional cost can create affordability challenges for price-sensitive patients, particularly those requiring regular insulin injections, potentially limiting the adoption of advanced pen needle products.

03

Impact Analysis of Key Restraints in Pen Needles Market

01

Development of Pen Needles for Pediatric and Neonatal Patients

Medical device manufacturers, pediatric diabetes care providers, and healthcare institutions can develop specialized pen needles with suitable lengths and designs for younger patients who require insulin administration. Revenue opportunities include specialized product sales, hospital supply contracts, and partnerships with pediatric diabetes care programs. Companies such as BD and Novo Nordisk have relevant diabetes injection device expertise.

02

Pen Needle Distribution Through Online Pharmacies

Pen needle manufacturers, pharmaceutical distributors, and digital pharmacy platforms can expand online availability to improve product accessibility for patients who require regular supplies. Commercial opportunities include direct-to-consumer sales, subscription-based replenishment services, bulk purchasing agreements, and partnerships with online pharmacies.

By Product Type

Standard Pen Needles are expected to register a CAGR of 7.96% during the forecast period, supported by their established use in insulin administration and compatibility with widely used pen devices.

Safety Pen Needles are anticipated to record a CAGR of 9.31% during the forecast period, driven by demand for safer injection practices, reduced needlestick injuries, and improved patient and healthcare worker protection.

Request Customization to receive a tailored report.

By Needle Length

The 4mm segment accounted for a share of 31.5% in 2025, supported by its suitability for subcutaneous injections, ease of use, and reduced risk of intramuscular injection.

A CAGR of 8.78% during the forecast period is anticipated for 5mm needles, driven by their suitability for different patient requirements and compatibility with pen-based injection devices.

By Therapy Type

The Insulin segment accounted for a share of 68.7% in 2025, owing to the widespread use of insulin therapy for blood glucose management among people with diabetes.

GLP-1 therapy is expected to record a CAGR of 10.36% during the forecast period, driven by increasing adoption of GLP-1 medications for diabetes management and weight control.

By Usability

Reusable Pens are projected to register a CAGR of 7.88% during the forecast period, supported by their repeated use, compatibility with replaceable cartridges, and suitability for long-term therapy.

Disposable Pens are anticipated to record a CAGR of 9.16% during the forecast period, driven by convenience, reduced handling requirements, and improved ease of use for patients.

By Mode Of Distribution

Retail distribution is expected to register a CAGR of 8.58% during the forecast period, supported by the accessibility of medical supplies through pharmacies and other retail outlets.

Non-retail distribution is anticipated to record a CAGR of 8.03% during the forecast period, driven by institutional procurement and supply requirements across hospitals, clinics, and healthcare facilities.

Speak to an Analyst to discuss market opportunities.

Pen Needles Market Regional OutlookNorth America Pen Needles Market

The North America pen needles market accounted for a dominant share of 38.6% in 2025.

U.S. Pen Needles Market

The U.S. has an established diabetes management ecosystem supported by healthcare providers, pharmacies, and medical device manufacturers. Patients with diabetes use insulin pens and compatible pen needles for convenient and controlled insulin administration. The availability of different needle lengths, gauges, and safety-engineered designs supports product adoption across hospitals and home healthcare settings.

Canada Pen Needles Market

Canada's established diabetes care services and access to insulin delivery devices support demand for pen needles. Healthcare providers and patients use pen-based injection systems for routine insulin administration and diabetes management. Pharmacy distribution networks, public healthcare services, and increasing emphasis on convenient self-administration support product availability.

Unlock Regional Insights to access country-level data, & regional trends.

Europe Pen Needles Market

Europe pen needles market is the fastest-growing region in the Pen Needles Market with a CAGR of 9.28% during the forecast period, making it the fastest-growing regional market.

U.K. Pen Needles Market

The U.K.'s established diabetes care infrastructure and access to insulin therapies support demand for pen needles. Healthcare providers prescribe insulin pen systems for patients requiring routine insulin administration, while home-based diabetes management supports the use of disposable pen needles. Product availability through pharmacies and healthcare services further contributes to adoption.

Germany Pen Needles Market

Germany's established healthcare system, pharmaceutical industry, and medical device sector support demand for pen needles. Patients and healthcare providers use insulin pen systems for convenient and controlled medication delivery. The availability of advanced injection devices, safety-focused needle designs, and established medical supply distribution channels supports market adoption.

Asia Pacific Pen Needles Market

Asia Pacific pen needles market is projected to register a CAGR of 8.74% during the forecast period.

China Pen Needles Market

China's expanding diabetes care infrastructure and pharmaceutical distribution network support demand for pen needles. The use of insulin pen devices across hospitals, clinics, and home healthcare settings creates demand for compatible disposable needles. Wider access to diabetes treatment and the availability of different injection device options further support adoption.

India Pen Needles Market

India's expanding diabetes treatment infrastructure and increasing access to insulin delivery devices support demand for pen needles. Patients use insulin pens for routine medication administration, particularly in outpatient and home healthcare settings. Pharmaceutical distribution networks, medical device availability, and increasing awareness of diabetes management contribute to product adoption.

Japan Pen Needles Market

Japan's established healthcare infrastructure and advanced medical device industry support demand for pen needles. Insulin pen systems are used across hospitals, outpatient facilities, and home healthcare environments for diabetes management. Demand for convenient injection methods, precision-engineered needles, and patient-friendly medical devices further supports adoption.

Competitive Landscape

The pen needles market is moderately consolidated, with competition involving medical device manufacturers, diabetes care product developers, injection technology providers, and specialized needle manufacturers. The leading players in the market include BD, Novo Nordisk, and Ypsomed, accounting for 30–35% of the global pen needles market share.

Established players compete primarily on needle sharpness, injection comfort, product safety, manufacturing precision, compatibility with insulin pens, regulatory compliance, and global distribution networks. Emerging and specialized players in the pen needles market ecosystem compete through ultra-thin needle designs, advanced lubrication technologies, reduced injection pain, improved patient-friendly features, innovative safety mechanisms, and cost-effective solutions for diabetes management.

List of Key and Emerging Players in Pen Needles Market Links Medical Product Becton, Dickinson and Company (U.S.) Novo Nordisk A/S (Denmark) B. Braun Melsungen AG (Germany) Ypsomed Holding AG (Switzerland) Owen Mumford Ltd. (United Kingdom AdvaCare Pharma (U.S.) Montmed Inc. (U.S.) Allison Medical (U.S.) Terumo Corporation (Japan) UltiMed, Inc. (U.S. Van Heek Medical (Netherlands) HTL-STREFA S.A. (Poland) Hindustan Syringes & Medical Devices Ltd. (India) Igaku Needles (Japan) Links Medical Products Inc. (Canada) Medexel Co., Ltd. (South Korea) Narang Medical Limited (India) Medivena (Germany) Nipro Europe Group Companies (Netherlands)Key Industry Developments June 2026 – Medtronic Launches InPenTM App Integration with SimpleraTM Sync CGM
Medtronic introduced integration between its InPenTM smart insulin pen system and the SimpleraTM Sync continuous glucose monitoring (CGM) sensor. The enhancement enables real-time glucose insights and optimized insulin dose recommendations, improving the overall smart insulin injection ecosystem that utilizes disposable pen needles. May 2026 – Embecta Expands Pen Needle Portfolio with Enhanced Safety Features
Embecta Corp. expanded its diabetes injection portfolio by introducing advanced safety-engineered pen needles designed to minimize accidental needlestick injuries while improving patient comfort. The new products support insulin and GLP-1 therapy across hospital and home-care settings. February 2026 – Owen Mumford Enhances Unifine® Pentips® Range
Owen Mumford expanded its Unifine® Pentips® pen needle portfolio with improved ultra-thin wall technology and optimized needle geometry to reduce injection force and enhance patient comfort for diabetes management. The products are compatible with major insulin and GLP-1 injection pens ScopeSegmentation By Product Type 2
    Standard Pen Needles Safety Pen Needles
By Needle Length 6
    4mm 5mm 6mm 8mm 10mm 12mm
By Therapy Type 5
    Insulin GLP-1 Growth Hormone Therapy Obesity Others
By Usability 2
    Reusable Pens Disposable Pens
By Mode of Distribution 2
    Retail Non-retail
Geographies Covered North America 2
    U.S. Canada
Europe 8
    U.K. Germany France Spain Italy Russia Nordic Benelux
APAC 7
    China Korea Japan India Australia Taiwan South East Asia
Middle East and Africa 6
    UAE Turkey Saudi Arabia South Africa Egypt Nigeria
LATAM 5
    Brazil Mexico Argentina Chile Colombia
Competitive Coverage Links Medical Products · Becton, Dickinson and Company (U.S.) · Novo Nordisk A/S (Denmark) · B. Braun Melsungen AG (Germany) · Ypsomed Holding AG (Switzerland) Research Deliverables Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends

Customize This Report to Match Your Strategic Objectives

Frequently Asked Questions (FAQs) The pen needles market size is valued at USD 4.17 Billion in 2026 and is projected to reach USD 10.10 Billion by 2034, at a CAGR of 11.7% during the forecast period 2026-2034. North America dominated the market with a share of 38.6% in 2025. The leading players in this market are BD, Novo Nordisk, B. Braun Melsungen AG, Ypsomed Holding AG, Owen Mumford Ltd. The pen needles market is projected to grow at a CAGR of 11.7% during the forecast period of 2026 2034.

MENAFN19112026004597010906ID1111988317


Straits Research

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.



More Story

Search